Balkus Jennifer E, Brown Elizabeth R, Hillier Sharon L, Coletti Anne, Ramjee Gita, Mgodi Nyaradzo, Makanani Bonus, Reid Cheri, Martinson Francis, Soto-Torres Lydia, Abdool Karim Salim S, Chirenje Zvavahera M
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Contraception. 2016 Jan;93(1):25-31. doi: 10.1016/j.contraception.2015.10.010. Epub 2015 Oct 28.
To assess the effect of oral and injectable contraceptive use compared to nonhormonal contraceptive use on HIV acquisition among Southern African women enrolled in a microbicide trial.
This is a prospective cohort study using data from women enrolled in HIV Prevention Trials Network protocol 035. At each quarterly visit, participants were interviewed about self-reported contraceptive use and sexual behaviors and underwent HIV testing. Cox proportional hazards regression was used to assess the effect of injectable and oral hormonal contraceptive use on HIV acquisition.
The analysis included 2830 participants, of whom 106 became HIV infected (4.07 per 100 person-years). At baseline, 1546 (51%) participants reported using injectable contraceptives and 595 (21%) reported using oral contraceptives. HIV incidence among injectable, oral and nonhormonal contraceptive method users was 4.72, 2.68 and 3.83 per 100 person-years, respectively. Injectable contraceptive use was associated with a nonstatistically significant increased risk of HIV acquisition [adjusted hazard ratio (aHR)=1.17; 95% confidence interval (CI) 0.70, 1.96], while oral contraceptive use was associated with a nonstatistically significant decreased risk of HIV acquisition (aHR=0.76; 95% CI 0.37,1.55).
In this secondary analysis of randomized trial data, a marginal, but nonstatistically significant, increase in HIV risk among women using injectable hormonal contraceptives was observed. No increased HIV risk was observed among women using oral contraceptives. Our findings support the World Health Organization's recommendation that women at high risk for acquiring HIV, including those using progestogen-only injectable contraception, should be strongly advised to always use condoms and other HIV prevention measures.
Among Southern African women participating in an HIV prevention trial, women using injectable hormonal contraceptives had a modest increased risk of HIV acquisition; however, this association was not statistically significant. Continued research on the relationship between widely used hormonal contraceptive methods and HIV acquisition is essential.
评估在参加一项杀微生物剂试验的南部非洲女性中,口服和注射用避孕药与非激素避孕药相比对感染艾滋病毒的影响。
这是一项前瞻性队列研究,使用来自参与艾滋病毒预防试验网络方案035的女性的数据。在每季度的访视中,对参与者进行关于自我报告的避孕方法使用情况和性行为的访谈,并进行艾滋病毒检测。采用Cox比例风险回归来评估注射用和口服激素避孕药对感染艾滋病毒的影响。
分析纳入了2830名参与者,其中106人感染了艾滋病毒(每100人年4.07例)。在基线时,1546名(51%)参与者报告使用注射用避孕药,595名(21%)报告使用口服避孕药。注射用、口服和非激素避孕方法使用者中的艾滋病毒发病率分别为每100人年4.72例、2.68例和3.83例。使用注射用避孕药与感染艾滋病毒的风险增加但无统计学意义相关[调整后风险比(aHR)=1.17;95%置信区间(CI)0.70,1.96],而使用口服避孕药与感染艾滋病毒的风险降低但无统计学意义相关(aHR=0.76;95%CI 0.37,1.55)。
在这项对随机试验数据的二次分析中,观察到使用注射用激素避孕药的女性感染艾滋病毒的风险有边际增加,但无统计学意义。使用口服避孕药的女性未观察到感染艾滋病毒风险增加。我们的研究结果支持世界卫生组织的建议,即应强烈建议有感染艾滋病毒高风险的女性,包括那些仅使用注射用孕激素避孕药的女性,始终使用避孕套和其他艾滋病毒预防措施。
在参加艾滋病毒预防试验的南部非洲女性中,使用注射用激素避孕药的女性感染艾滋病毒的风险有适度增加;然而,这种关联无统计学意义。继续研究广泛使用的激素避孕方法与感染艾滋病毒之间的关系至关重要。